Review article: Gut flora and inflammatory bowel disease

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 20, Issue 4, 2004, Pages 18-23

  Marteau, P ^a   Lepage, P ^b   Mangin, I ^c   Suau, A ^c   Dore J ^b   Pochart, P ^c   Seksik, P ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b CEMAGREF   (France)

^c Bioinformatique et Chimie Moléculaire   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; PREBIOTIC AGENT; PROBIOTIC AGENT;

CLINICAL TRIAL; ENTERITIS; GASTROINTESTINAL TRACT; GENETIC VARIABILITY; HOST SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; INTESTINE FLORA; MUCOSAL IMMUNITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

BACTERIA; BACTERIAL ADHESION; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; INTESTINES;

EID: 4844220199     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Marteau P, Seksik P, Shanahan F. Manipulation of the bacterial flora in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2003; 17: 47-61.
2. Bhan AK, Mizoguchi E, Smith RN, Mizoguchi A. Colitis in transgenic and knockout animals as models of human inflammatory bowel disease. Immunol Rev 1999; 169: 195-207.
3. Cong Y, Brandwein SL, McCabe RP, et al. CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J Exp Med 1998; 187: 855-64.
4. Harper PH, Lee ECG, Kettlewell MGW, et al. Rolez of the faecal stream in the maintenance of Crohn's colitis. Gut 1985; 26: 279-84.
5. Gionchetti P, Amadini C, Rizzello F, Venturi A, Poggioli G, Campieri M. Probiotics for the treatment of postoperative complications following intestinal surgery. Best Pract Res Clin Gastroenterol 2003; 17: 821-31.
6. Marteau P, Shanahan F. Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. Best Pract Res Clin Gastroenterol 2003; 17: 725-40.
7. Guarner F, Malagelada JR. Role of bacteria in experimental colitis. Best Pract Res Clin Gastroenterol 2003; 17: 793-804.
8. Obermeier F, Dunger N, Deml L, Herfarth H, Scholmerich J, Falk W. CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice. Eur J Immunol 2002; 32: 2084-92.
9. Tamboli CP, Caucheteux C, Cortot A, Colombel JF, Desreumaux P. Probiotics in inflammatory bowel disease: a critical review. Best Pract Res Clin Gastroenterol 2003; 17: 805-20.
10. Chen W, Li D, Wilson I, Chadwick VS. Detection of Chlamydia pneumoniae by polymerase chain reaction-enzyme immunoassay in intestinal mucosal biopsies from patients with inflammatory bowel disease and controls. J Gastroenterol Hepatol 2002; 17: 987-93.
11. Huijsdens XW, Linskens RK, Taspinar H, Meuwissen SG, Vandenbroucke-Grauls CM, Savelkoul PH. Listeria monocytogenes and inflammatory bowel disease. detection of Listeria species in intestinal mucosal biopsies by real-time PCR. Scand J Gastroenterol 2003; 38: 332-3.
12. Chen W, Li D, Paulus B, Wilson I, Chadwick VS. Detection of Listeria monocytogenes by polymerase chain reaction in intestinal mucosal biopsies from patients with inflammatory bowel disease and controls. J Gastroenterol Hepatol 2000; 15: 1145-50.
13. Van Kruiningen HJ. Lack of support for a common etiology in Johne's disease of animals and Crohn's disease in humans. Inflamm Bowel Dis 1999; 5: 183-91.
14. Sghir A, Gramet G, Suau A, Rochet V, Pochart P, Dore J. Quantification of bacterial groups within human fecal flora by oligonucleotide probe hybridization. Appl Environ Microbiol 2000; 66: 2263-6.
15. Marteau P, Pochart P, Dore J, Bera-Maillet C, Bernalier A, Corthier G. Comparative study of bacterial groups within the human cecal and fecal microbiota. Appl Environ Microbiol 2001; 67: 4939-42.
16. Schultsz C, Van Den Berg FM, Ten Kate FW, Tytgat GN, Dankert J. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology 1999; 117: 1089-97.
17. Kleessen B, Kroesen AJ, Buhr HJ, Blaut M. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand J Gastroenterol 2002; 37: 1034-41.
18. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122: 44-54.
19. Zoetendal EG, von Wright A, Vilpponen-Salmela T, Ben-Amor K, Akkermans AD, de Vos WM. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol 2002; 68: 3401-7.
20. Blaut M, Collins MD, Welling GW, Dore J, van Loo J, de Vos W. Molecular biological methods for studying the gut microbiota: the EU human gut flora project. Br J Nutr 2002; 87(Suppl. 2): S203-11.
21. Seksik P, Rigottier-Gois L, Gramet G, et al. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 2003; 52: 237-42.
22. Zoetendal EG, Akkermans AD, De Vos WM. Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl Environ Microbiol 1998; 64: 3854-9.
23. Heilig HG, Zoetendal EG, Vaughan EE, Marteau P, Akkermans AD, de Vos WM. Molecular diversity of Lactobacillus spp. and other lactic acid bacteria in the human intestine as determined by specific amplification of 16S ribosomal DNA. Appl Environ Microbiol 2002; 68: 114-23.
24. Zoetendal E, Akkermans A, Akkermans-van Vliet W, Visser J, de Vos W. The host genotype affects the bacterial community in the human gastrointestinal tract. Microbial Ecol Health Dis 2001; 13: 129-34.
25. Mangin I, Bonnet R, Seksik Ph, et al. Specificities of fecal microbiota of four Crohn's disease patients evidenced by culture-independent analysis of dominant species distribution. Gastroenterology 2003; 124(Suppl. 1): S1370(Abstract).
26. Gorbach SL, Nahas L, Plaut AG, et al. Studies of intestinal microflora. V. Fecal microbial ecology in ulcerative colitis and regional enteritis: relationship to severity of disease and chemotherapy. Gastroenterology 1968; 54: 575-87.
27. Tabaqchali S, O'Donoghue DP, Bettelheim KA. Escherichia coli antibodies in patients with inflammatory bowel disease. Gut 1978; 19: 108-13.
28. Keighley MR, Arabi Y, Dimock F, et al. Influence of inflammatory bowel disease on intestinal microflora. Gut 1978; 19: 1099-104.
29. Dickinson RJ, Varian SA, Axon AT, Cooke EM. Increased incidence of faecal coliforms with in vitro adhesive and invasive properties in patients with ulcerative colitis. Gut 1980; 21: 787-972.
30. Giaffer MH, Holdsworth CD, Duerden BI. The assessment of faecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique. J Med Microbiol 1991; 35: 238-43.
31. Fabia R, Ar'Rajab A, Johansson ML, et al. Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat. Digestion 1993; 54: 248-55.
32. Van de Merwe JP, Schroder AM, Wensinck F, Hazenberg MP. The obligate anaerobic faecal flora of patients with Crohn's disease and their first-degree relatives. Scand J Gastroenterol 1988; 23: 1125-31.
33. Ruseler-van Embden JG, Both-Patoir HC. Anaerobic gram-negative faecal flora in patients with Crohn's disease and healthy subjects. Antonie Van Leeuwenhoek 1983; 49: 125-32.
34. Favier C, Neut C, Mizon C, Cortot A, Colombel JF, Mizon J. Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease. Dig Dis Sci 1997; 42: 817-22.
35. Rath HC, Ikeda JS, Linde HJ, Scholmerich J, Wilson KH, Sartor RB. Varying cecal bacterial load influences colitis and gastritis in HLA-B27 transgenic rats. Gastroenterology 1999; 116: 310-9.
36. Lepage P, Seksik Ph, De La Cochetière MF, et al. Molecular study of the ileal and colonic mucosa associated microflora in IBD. Gastroenterology 2003; 124(Suppl. 1): T1066(Abstract).
37. Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998; 11: 1405-13.
38. Masseret E, Boudeau J, Colombel JF, et al. Genetically related Escherichia coli strains associated with Crohn's disease. Gut 2001; 48: 320-5.
39. Neut C, Bulois P, Desreumaux P, et al. Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol 2002; 97: 939-46.
40. Darfeuille-Michaud A. Adherent-invasive Escherichia coli: a putative new E. coli pathotype associated with Crohn's disease. Int J Med Microbiol 2002: 292: 185-93.
41. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 305-9.
42. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL #3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53: 108-14.
43. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 12: 1202-9.
44. Campieri M, Rizzello F, Venturi A, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomized controlled study vs. mesalamine. Gastroenterology 2000; 118: G4179.
45. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000; 45: 1462-4.
46. Copaci I, Micu L, Chira C, Rovinaru I. Maintenance of remission of ulcerative colitis (UC): mesalamine, dietary fiber, S. boulardii. Gut 2000; 47(Suppl. III): A240, P929.
47. Kruis W, Schütz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853-8.
48. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 635-9.
49. Kruis W, Fric P, Stolte M. Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli Nissle 1997 and with standard mesalamine. Gastroenterology 2001; 120: A139(Abstract).
50. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997; 25: 653-8.
51. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002; 51: 405-9.
52. Ishikawa H, Akedo I, Umesaki Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003; 22: 56-63.
53. Steidler L. Genetically engineered probiotics. Best Pract Res Clin Gastroenterol 2003; 17: 861-76.